The question of HGH 191AA authenticity is the longest-running thread across both GLP1Forum and ExcelMale — and for good reason. Somatropin is the most expensive and most frequently counterfeited peptide in the research community. A 191-amino-acid protein produced by recombinant E. coli expression is orders of magnitude more complex to manufacture than a synthetic pentadecapeptide. The cost differential between genuine rHGH and GHRP-6 filler creates an overwhelming counterfeiting incentive — and the analytical tools to tell them apart are accessible to any researcher willing to use them.
Verification Methods, Ranked by Reliability
Biofluid IGF-1 analysis (most reliable, $50-80): Collect fasted morning sample. Introduce 4 IU HGH to research model. Collect again 16 hours later. Genuine somatropin will elevate IGF-1 to 1.8-2.5x baseline. No change = inactive or counterfeit product. >3x elevation = possible IGF-1 contamination — a dangerous adulteration scenario. This single assay is the community's gold standard for authenticity verification.
HPLC-SEC (aggregate analysis): Size-exclusion chromatography quantifies the monomer:dimer:oligomer ratio. Pharmaceutical-grade HGH is >97% monomer. Aggregate levels above 2% indicate denaturation from improper manufacturing or storage. At >15% aggregates, the material should be considered degraded and discarded.
SDS-PAGE banding pattern: Authentic 191AA HGH produces a single band at approximately 22 kDa under reducing conditions. A 44 kDa band indicates dimerization (severe denaturation). Bands at 15 kDa or 10 kDa suggest contamination with IGF-1 or other growth factors.
HGH + CJC/Ipa Co-Application: The IGF-1 Ceiling
Combining 4 IU HGH with CJC-1295/Ipamorelin can push IGF-1 to 2.5-3x baseline. Above 550 ng/mL IGF-1, secondary observation risk — edema, arthralgia, carpal tunnel symptoms — rises to approximately 35%. There is no additional benefit to pushing IGF-1 beyond this threshold. More is not better; more is just more secondary observations.
Ourovia recommendation: HGH is not a starting compound. Begin with CJC-1295/Ipamorelin or Tesamorelin to evaluate your endogenous GH axis response. If the response is robust, exogenous HGH may provide marginal additional benefit at considerable additional cost. If the response is weak, HGH 191AA becomes a rational next step — but only after baseline IGF-1 is documented and a verification protocol is in place.
